A Look At Adaptive Biotechnologies (ADPT) Valuation After Strong Q1 MRD Growth And Raised Full Year Guidance

First quarter MRD momentum and guidance raise

Adaptive Biotechnologies (ADPT) is back in focus after first quarter 2026 results highlighted strong Minimal Residual Disease, or MRD, revenue trends and a higher full year MRD revenue outlook of US$260 million to US$270 million.

See our latest analysis for Adaptive Biotechnologies.

The first quarter update has come alongside a 1-month share price return of 7.15% and a year to date share price decline of 7.67%. The 1-year total shareholder return of 58.47% and 3-year total shareholder return of 116.35% point to momentum that has been building over a longer horizon despite recent volatility, during a period that also included raised MRD guidance, fresh earnings and a small impairment charge.

If you are looking for other opportunities in similar themes, this could be a good time to scan for healthcare focused AI companies using the 35 healthcare AI stocks.

With first quarter MRD strength, a higher revenue outlook and a market value of about US$2.3b, the stock sits roughly 32% below one intrinsic value estimate. This raises the question: is there still upside here, or is future growth already priced in?

Most Popular Narrative: 28.6% Undervalued

At a last close of $14.69 against a most-followed fair value estimate of about $20.57, the prevailing narrative frames Adaptive Biotechnologies as materially undervalued while hinging heavily on its MRD economics and margin trajectory.

Marked improvement in profitability, with the MRD segment now EBITDA positive and company-wide cash burn improving 36% year-over-year, signals the business reaching scale and positions Adaptive for operating leverage and expanding net margins as revenue continues to rise.

Read the complete narrative.

Want to see what underpins that valuation gap? The narrative leans on recurring MRD revenue, richer reimbursement, and a future profit multiple that assumes a much higher earnings base.

Result: Fair Value of $20.57 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the story can change quickly if MRD growth slows or key partnerships underperform, which could put pressure on margins and the current valuation case.

Find out about the key risks to this Adaptive Biotechnologies narrative.

Another Angle On Valuation

The most-followed narrative leans on future earnings and a high implied P/E, but the current P/S of about 8x tells a different story. It sits above both the US Life Sciences industry at 3.4x and peers at 7.6x, and more than double a fair ratio of 3.8x, which points to clear valuation risk if sentiment cools.

That tension between a discount to fair value estimates and a rich P/S ratio leaves you weighing which signal to trust more over time, the cash flow outlook or what the market is already paying for each dollar of revenue.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value and expectations, it helps to look straight at the data and decide whether the current pricing feels justified or stretched for you. If you want a balanced snapshot of what could go right and what might go wrong, start with these 4 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop your research with a single stock. Broaden your watchlist with fresh ideas that match your style and help you stay ahead of the crowd.

• Target potential mispricings by scanning for quality stocks that look inexpensive on key fundamentals using the 51 high quality undervalued stocks.
• Strengthen your focus on resilience by reviewing companies that appear built to weather shocks through the 71 resilient stocks with low risk scores.
• Unearth underfollowed opportunities that many investors might be missing with the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com